GLP-1s tied to fewer knee replacements in OA

Clinical takeaway: For patients with knee OA already considering a GLP-1 drug for obesity or diabetes, these data suggest a possible joint benefit alongside the metabolic one.

Knee osteoarthritis has no disease-modifying drug treatment, with end-stage disease often leading to knee replacement. GLP-1 receptor agonists ease OA-related knee pain and may also help to protect cartilage, raising the question of whether they can delay surgery. This analysis asked whether that result shows up in real-world outcomes.

Patients taking a GLP-1 were less likely to undergo knee replacement at every follow-up point than matched patients who never took one, and the gap widened over time. With any GLP-1 agent taken for a year, about 3.4% of treated patients had surgery by eight years versus 6.2% of matched comparators, a 2.8 percentage point difference. At three years the gap was smaller, about 1.4 points.

The reductions were larger with the newer agents, semaglutide and tirzepatide, used over longer periods. With three years of either drug, roughly 1.8% had surgery by eight years versus 6.5% of comparators, a 4.7 point difference.

Progression to knee replacement is driven mainly by pain and function, not imaging severity, so the analgesic effect of GLP-1 drugs could reduce surgeries without altering the joint itself. The authors frame the finding as consistent with effects beyond weight loss alone, supported by preclinical signs of cartilage protection, but say the relative contributions of weight loss, pain relief, and direct tissue effects cannot be separated.

The study drew on a large electronic health record network, identifying roughly 6.7 million adults diagnosed with knee OA from 2010 to 2024. Each treated group was compared with propensity-matched patients who never received a GLP-1 prescription, balanced on age, sex, race, musculoskeletal and obesity-related diagnoses, BMI, and healthcare-access proxies. After matching, the treated cohorts ranged from about 13,000 to 42,000 patients.

Exposure was based on prescription orders, not confirmed fills, and the database lacks imaging severity, pain scores, and weight trajectories. Unmeasured factors such as frailty, activity level, and OA severity could not be fully controlled.

The authors conclude, “Clinically, these findings indicate that GLP-1 receptor agonists may represent a complementary strategy within non-surgical knee osteoarthritis management, particularly in metabolically high risk patients. However, more robust prospective studies incorporating defined patient phenotypes, GLP-1 receptor agonist dosing and duration, and objective measures of knee osteoarthritis progression are required to confirm these associations and guide clinical care.”

Source: Carter V. Reg Anesth Pain Med. 2026 Jun 2. Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis